Utilities Dividend & Income
SLNG Stabilis Solutions Inc
THO Thor Industries Inc
Go

Health Care : Pharmaceuticals | Small Cap Value

RespireRx Pharmaceuticals Inc. is engaged in the discovery and development of medicines for the treatment of psychiatric and neurological disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. It is developing a pipeline of new and re-purposed drug products based on its patent portfolios for two drug platforms: pharmaceutical cannabinoids platform, is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea (OSA) and neuromodulators platform includes AMPAkines that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors and GABAkines that are PAMs of GABAA receptors.

Closing Price: $0.0064

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: 0.0075

Day's Low: 0.0064

Volume (Below Average) Volume: 190,200 10-day average volume: 692,601: 190,200

May 24, 2022
8:00 am ET	RespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals Summit EQNX::TICKER_START (Other OTC:RSPI),(OTC US:RSPI), EQNX::TICKER_END RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases...(Globe Newswire)
May 17, 2022
8:00 am ET	RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics. EQNX::TICKER_START (Other OTC:RSPI),(OTC US:RSPI), EQNX::TICKER_END RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases...(Globe Newswire)
May 16, 2022
8:00 am ET	RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus EQNX::TICKER_START (Other OTC:RSPI),(OTC US:RSPI), EQNX::TICKER_END RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases...(Globe Newswire)
March 23, 2022
8:00 am ET	RespireRx Pharmaceuticals Inc. Announces Patent Filings Claiming Novel Lipid Based Formulations for Insoluble Compounds, Including Cannabinoids Such as Dronabinol RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, in association with...(Globe Newswire)
March 16, 2022
8:00 am ET	RespireRx Pharmaceuticals Inc. Announces Discovery of a New GABAkine Neuromodulator that Protects Against Seizures and Lethality RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)
March 07, 2022
8:00 am ET	Letter to Stockholders and Other Stakeholders: A Brief Summary of Our Progress During Past Twelve Months and a Peek Looking Forward RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to provide a...(Globe Newswire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and